Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - SOPHEON PLC

11 Jan 2024 08:49

RNS Number : 3925Z
Oddo BHF AIF PLC
11 January 2024
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Oddo BHF AIF PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

SOPHEON PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10/01/2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

20p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

260 300

2.43%

 

 

(2) Cash-settled derivatives:

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

TOTAL:

260 300

2.43%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

20p ordinary

Purchase

1 000

970.00 GBp

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 (c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

none

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

none

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

11/01/2024

Contact name:

Névine ZEMMOURI

 

+33 1 44 51 85 22

controleaif@oddo-bhf.com

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETGPUMCGUPCURG
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.